Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study.
Alveolitis
Early prognostic score
Haematological malignancies
High flow oxygen
Pneumocystis jirovecii pneumonia
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
27 Nov 2019
27 Nov 2019
Historique:
received:
26
07
2019
accepted:
13
11
2019
entrez:
29
11
2019
pubmed:
30
11
2019
medline:
30
11
2019
Statut:
epublish
Résumé
Pneumocystis jirovecii pneumonia (PJP) remains a severe disease associated with high rates of invasive mechanical ventilation (MV) and mortality. The objectives of this study were to assess early risk factors for severe PJP and 90-day mortality, including the broncho-alveolar lavage fluid cytology profiles at diagnosis. We prospectively enrolled all patients meeting pre-defined diagnostic criteria for PJP admitted at Nantes university hospital, France, from January 2012 to January 2017. Diagnostic criteria for PJP were typical clinical features with microbiological confirmation of P. jirovecii cysts by direct examination or a positive specific quantitative real-time polymerase chain reaction (PCR) assay. Severe PJP was defined as hypoxemic acute respiratory failure requiring high-flow nasal oxygen with at least 50% FiO Of 2446 respiratory samples investigated during the study period, 514 from 430 patients were positive for P. jirovecii. Of these 430 patients, 107 met criteria for PJP and were included in the study, 53 (49.5%) patients had severe PJP, including 30 who required MV. All patients were immunocompromised with haematological malignancy ranking first (n = 37, 35%), followed by solid organ transplantation (n = 27, 25%), HIV-infection (n = 21, 20%), systemic diseases (n = 13, 12%), solid tumors (n = 12, 11%) and primary immunodeficiency (n = 6, 8%). By multivariate analysis, factors independently associated with severity were older age (OR, 3.36; 95% CI 1.4-8.5; p < 0.05), a P. jirovecii microscopy-positive result from bronchoalveolar lavage (BAL) (OR, 1.3; 95% CI 1.54-9.3; p < 0.05); and absence of a BAL fluid alveolitis profile (OR, 3.2; 95% CI 1.27-8.8; p < 0.04). The 90-day mortality rate was 27%, increasing to 50% in the severe PJP group. Factors independently associated with 90-day mortality were worse SOFA score on day 1 (OR, 1.05; 95% CI 1.02-1.09; p < 0.001) whereas alveolitis at BAL was protective (OR, 0.79; 95% CI 0.65-0.96; p < 0.05). In the subgroup of HIV-negative patients, similar findings were obtained, then viral co-infection were independently associated with higher 90-day mortality (OR, 1.25; 95% CI 1.02-1.55; p < 0.05). Older age and P. jirovecii oocysts at microscopic examination of BAL were independently associated with severe PJP. Both initial PJP severity as evaluated by the SOFA score and viral co-infection predicted 90-day mortality. Alveolitis at BAL examination was associated with less severe PJP. The pathophysiological mechanism underlying this observation deserves further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Pneumocystis jirovecii pneumonia (PJP) remains a severe disease associated with high rates of invasive mechanical ventilation (MV) and mortality. The objectives of this study were to assess early risk factors for severe PJP and 90-day mortality, including the broncho-alveolar lavage fluid cytology profiles at diagnosis.
METHODS
METHODS
We prospectively enrolled all patients meeting pre-defined diagnostic criteria for PJP admitted at Nantes university hospital, France, from January 2012 to January 2017. Diagnostic criteria for PJP were typical clinical features with microbiological confirmation of P. jirovecii cysts by direct examination or a positive specific quantitative real-time polymerase chain reaction (PCR) assay. Severe PJP was defined as hypoxemic acute respiratory failure requiring high-flow nasal oxygen with at least 50% FiO
RESULTS
RESULTS
Of 2446 respiratory samples investigated during the study period, 514 from 430 patients were positive for P. jirovecii. Of these 430 patients, 107 met criteria for PJP and were included in the study, 53 (49.5%) patients had severe PJP, including 30 who required MV. All patients were immunocompromised with haematological malignancy ranking first (n = 37, 35%), followed by solid organ transplantation (n = 27, 25%), HIV-infection (n = 21, 20%), systemic diseases (n = 13, 12%), solid tumors (n = 12, 11%) and primary immunodeficiency (n = 6, 8%). By multivariate analysis, factors independently associated with severity were older age (OR, 3.36; 95% CI 1.4-8.5; p < 0.05), a P. jirovecii microscopy-positive result from bronchoalveolar lavage (BAL) (OR, 1.3; 95% CI 1.54-9.3; p < 0.05); and absence of a BAL fluid alveolitis profile (OR, 3.2; 95% CI 1.27-8.8; p < 0.04). The 90-day mortality rate was 27%, increasing to 50% in the severe PJP group. Factors independently associated with 90-day mortality were worse SOFA score on day 1 (OR, 1.05; 95% CI 1.02-1.09; p < 0.001) whereas alveolitis at BAL was protective (OR, 0.79; 95% CI 0.65-0.96; p < 0.05). In the subgroup of HIV-negative patients, similar findings were obtained, then viral co-infection were independently associated with higher 90-day mortality (OR, 1.25; 95% CI 1.02-1.55; p < 0.05).
CONCLUSIONS
CONCLUSIONS
Older age and P. jirovecii oocysts at microscopic examination of BAL were independently associated with severe PJP. Both initial PJP severity as evaluated by the SOFA score and viral co-infection predicted 90-day mortality. Alveolitis at BAL examination was associated with less severe PJP. The pathophysiological mechanism underlying this observation deserves further investigation.
Identifiants
pubmed: 31776705
doi: 10.1186/s13613-019-0604-x
pii: 10.1186/s13613-019-0604-x
pmc: PMC6881486
doi:
Types de publication
Journal Article
Langues
eng
Pagination
131Références
JAMA. 1992 Feb 12;267(6):832-7
pubmed: 1732656
Chest. 2013 Jul;144(1):258-265
pubmed: 23258406
Intensive Care Med. 2006 Oct;32(10):1560-8
pubmed: 16896863
Respir Care. 2005 May;50(5):604-9
pubmed: 15871753
Clin Infect Dis. 2014 Jun;58(11):1587-98
pubmed: 24585557
Chest. 2005 Aug;128(2):573-9
pubmed: 16100140
Chest. 2000 Sep;118(3):712-20
pubmed: 10988193
Arch Pathol Lab Med. 2017 Dec;141(12):1719-1727
pubmed: 28613912
J Infect Chemother. 2014 Feb;20(2):109-14
pubmed: 24480550
Clin Infect Dis. 1999 Sep;29(3):670-2
pubmed: 10530464
J Antimicrob Chemother. 1996 May;37 Suppl B:33-53
pubmed: 8818828
Crit Care. 2018 Nov 19;22(1):307
pubmed: 30454031
Emerg Infect Dis. 2014 Sep;20(9):1490-7
pubmed: 25148074
Lab Invest. 2006 Aug;86(8):790-9
pubmed: 16855596
Clin Infect Dis. 2002 Apr 15;34(8):1098-107
pubmed: 11914999
N Engl J Med. 1990 Nov 22;323(21):1444-50
pubmed: 2233916
J Infect. 2003 Jul;47(1):19-27
pubmed: 12850158
Eur J Clin Microbiol Infect Dis. 2006 Jun;25(6):382-8
pubmed: 16767486
Clin Infect Dis. 2002 Oct 15;35(8):929-34
pubmed: 12355379
Am J Respir Crit Care Med. 1999 Aug;160(2):493-9
pubmed: 10430719
Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):523-31
pubmed: 12172743
Am J Respir Crit Care Med. 2018 Dec 15;198(12):1519-1526
pubmed: 29995433
Crit Care. 2012 Dec 12;16(2):R46
pubmed: 22417886
Respir Res. 2013 Aug 28;14:87
pubmed: 23981859
Infect Immun. 2015 Oct 19;84(1):108-19
pubmed: 26483405
Am J Respir Crit Care Med. 2011 Jan 1;183(1):96-128
pubmed: 21193785
N Engl J Med. 1990 Nov 22;323(21):1451-7
pubmed: 2233917
Clin Ter. 2017 Mar-Apr;168(2):e140-e145
pubmed: 28383627
Infect Chemother. 2018 Jun;50(2):110-119
pubmed: 29968978
J Infect Dis. 2011 Aug 15;204(4):544-53
pubmed: 21791656
AIDS. 1991 May;5(5):527-33
pubmed: 1863404
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Infect. 2014 Jul;69(1):88-95
pubmed: 24607411
Am Rev Respir Dis. 1989 Nov;140(5):1204-9
pubmed: 2817582
Ann Rheum Dis. 2015 Dec;74(12):2107-16
pubmed: 26395500
Crit Care. 2008;12(1):R28
pubmed: 18304356
J Clin Microbiol. 2015 Apr;53(4):1310-6
pubmed: 25673796
Clin Transl Immunology. 2014 Feb 28;3(2):e12
pubmed: 25505960
J Infect Chemother. 2014 Jul;20(7):412-6
pubmed: 24767467
Scand J Infect Dis. 2004;36(11-12):848-54
pubmed: 15764172
Chest. 2007 Oct;132(4):1305-10
pubmed: 17934116
Scand J Infect Dis. 2014 Mar;46(3):210-4
pubmed: 24450839
Cochrane Database Syst Rev. 2015 Apr 02;(4):CD006150
pubmed: 25835432
J Crit Care. 2014 Jun;29(3):356-61
pubmed: 24440053
Med Mycol. 2010 Dec;48(8):1075-87
pubmed: 20470237
Intensive Care Med. 2017 Dec;43(12):1808-1819
pubmed: 28948369
Int J Infect Dis. 2009 Jan;13(1):59-66
pubmed: 18573675
J Intensive Care. 2018 Aug 8;6:46
pubmed: 30116532
Chest. 1998 May;113(5):1215-24
pubmed: 9596297